Terms: = Brain cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
808 results:
1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon pd-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
2. Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-pd1/PD-L1 treatment in glioblastoma patients.
Wang Y; Wang Z; Guo X; Cao Y; Xing H; Wang Y; Xing B; Wang Y; Yao Y; Ma W
Cancer Med; 2024 May; 13(9):e7218. PubMed ID: 38733169
[TBL] [Abstract] [Full Text] [Related]
3. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-pd-1 monoclonal antibody for cancer immunotherapy.
Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
[TBL] [Abstract] [Full Text] [Related]
4. Vaccimel immunization is associated with enhanced response to treatment with anti-pd-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
[TBL] [Abstract] [Full Text] [Related]
5. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of pd-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer.
Li L; Xu C; Wang W; Zhang Q
Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297
[TBL] [Abstract] [Full Text] [Related]
7. Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of
Liu Z; Yang L; Xie Z; Yu H; Gu T; Shi D; Cai N; Zhuo S
Oncol Res; 2024; 32(5):965-981. PubMed ID: 38686055
[TBL] [Abstract] [Full Text] [Related]
8. Adaptive immune changes associate with clinical progression of Alzheimer's disease.
van Olst L; Kamermans A; Halters S; van der Pol SMA; Rodriguez E; Verberk IMW; Verberk SGS; Wessels DWR; Rodriguez-Mogeda C; Verhoeff J; Wouters D; Van den Bossche J; Garcia-Vallejo JJ; Lemstra AW; Witte ME; van der Flier WM; Teunissen CE; de Vries HE
Mol Neurodegener; 2024 Apr; 19(1):38. PubMed ID: 38658964
[TBL] [Abstract] [Full Text] [Related]
9. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
[TBL] [Abstract] [Full Text] [Related]
10. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages.
Xiao J; Wang S; Chen L; Ding X; Dang Y; Han M; Zheng Y; Shen H; Wu S; Wang M; Yang D; Li N; Dong C; Hu M; Su C; Li W; Hui L; Ye Y; Tang H; Wei B; Wang H
Immunity; 2024 May; 57(5):1087-1104.e7. PubMed ID: 38640930
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of the sodium pump subunit ATP1A3 in glioma patients: Potential value in prognostic prediction and immunotherapy.
Lan YL; Zou S; Qin B; Zhu X
Int Immunopharmacol; 2024 May; 133():112045. PubMed ID: 38615384
[TBL] [Abstract] [Full Text] [Related]
13. pd-1/PD-L1 axis is involved in the interaction between microglial polarization and glioma.
Wang XP; Guo W; Chen YF; Hong C; Ji J; Zhang XY; Dong YF; Sun XL
Int Immunopharmacol; 2024 May; 133():112074. PubMed ID: 38615383
[TBL] [Abstract] [Full Text] [Related]
14. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung cancer Treated with pd-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
15. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
Wang T; Zhang L; Cheng Y
Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
[TBL] [Abstract] [Full Text] [Related]
16. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract] [Full Text] [Related]
17. CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-pd-1 therapy.
Pant A; Hwa-Lin Bergsneider B; Srivastava S; Kim T; Jain A; Bom S; Shah P; Kannapadi N; Patel K; Choi J; Cho KB; Verma R; Yu-Ju Wu C; Brem H; Tyler B; Pardoll DM; Jackson C; Lim M
Oncoimmunology; 2024; 13(1):2338965. PubMed ID: 38590799
[TBL] [Abstract] [Full Text] [Related]
18. Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
Divan HA; Bittoni MA; Krishna A; Carbone DP
BMC Cancer; 2024 Apr; 24(1):424. PubMed ID: 38580900
[TBL] [Abstract] [Full Text] [Related]
19. Associations of pd-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
20. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A; Touat M; Belin L; Gourmelon C; Harlay V; Cuzzubbo S; Cohen-Jonathan Moyal E; Bronnimann C; Di Stefano AL; Laurent I; Lerond J; Carpentier C; Bielle F; Ducray F; Dehais C;
Eur J Cancer; 2024 May; 202():114034. PubMed ID: 38537315
[TBL] [Abstract] [Full Text] [Related]
[Next]
